Choose a language and wait for the translated text.
The domestic market sales tracker, PharmaTrac, in its latest reporting cycle βJuneβ sharply upgraded its 2026 growth forecast to 11.3 per cent from an earlier estimate of 8.1 per cent, citing stronger-than-expected trends in the first half of the year.
IPM 2026 growth outlook upgraded to 11.3% on strong H1 momentum | PharmaVoice
